Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: A comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan

American Journal of Cardiovascular Drugs

Volumn 5, Issue 1, 2005, Pages 41-50

  Smith, David H G ^a,b   Dubiel, Robert ^c   Jones, Michael ^c  

^a Integrium   (United States)

^b Memorial Research Medical Clinic   (United States)

^c DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; IRBESARTAN; LOSARTAN POTASSIUM; OLMESARTAN; VALSARTAN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; SINGLE-BLIND METHOD; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VALINE;

EID: 12744269551     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200505010-00006     Document Type: Article

References (24)

1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42 (6): 1206-52
2. Oparil S, Silfani TN, Walker JF. Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens. In press
3. Singer GM, Izhar M, Black HR. Goal-oriented hypertension management: translating clinical trials to practice. Hypertension 2002 Oct; 40 (4): 464-9
4. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood pressure recordings in patients with treated hypertension. N Engl J Med 2003 Jun 12; 348 (24): 2407-15
5. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension: Systolic Hypertension in Europe Trial Investigators. JAMA 1999 Aug 11; 282 (6): 539-46
6. Mancia G, Zanchetti A, Agabiti-Rosei E, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy: SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997 Mar 18; 95 (6): 1464-70
7. Gibbs CR, Murray S, Beevers DG. The clinical value of ambulatory blood pressure monitoring. Heart 1998 Feb; 79 (2): 115-7
8. White WB. Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit 2001 Apr; 6 (2): 63-72
9. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989 Apr; 79 (4): 733-43
10. Marler JR, Price TR, Clark GL, et al. Morning increase in onset of ischemic stroke. Stroke 1989 Apr; 20 (4): 473-6
11. White WB. Circadian variation of blood pressure: clinical relevance and implications for cardiovascular chronotherapeutics. Blood Press Monit 1997 Dec; 2 (1): 47-51
12. McGrath BP. Ambulatory blood pressure monitoring. Med J Aust 2002 Jun 17; 176 (12): 588-92
13. Myers MG, Haynes RB, Rabkin SW. Canadian hypertension society guidelines for ambulatory blood pressure monitoring. Am J Hypertens 1999 Nov; 12 (11 Pt 1): 1149-57
14. O'Brien E, Coats A, Owens P, et al. Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. BMJ 2000 Apr 22; 320 (7242): 1128-34
15. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001 Sep-Oct; 3 (5): 283-91, 318
16. Hommel G. A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika 1988; 75: 383-6
17. Byyny RL. Antihypertensive efficacy of the angiotensin II AT1-receptor antagonist losartan: results of a randomized, double-blind, placebo-controlled, parallel-group trial using 24-hour blood pressure monitoring. Ambulatory Blood Pressure Monitoring Study Group. Blood Press Suppl 1996; 2: 71-7
18. Fogari R, Ambrosoli S, Corradi L, et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring: Irbesartan Multicenter Investigators Group. J Hypertens 1997 Dec; 15 (12 Pt 1): 1511-8
19. Neutel J, Weber M, Pool J, et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther 1997 May-Jun; 19 (3): 447-58; discussion 367-8
20. Neutel JM, Elliott WJ, Izzo JL, et al. Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. J Clin Hypertens (Greenwich) 2002 Sep-Oct; 4 (5): 325-31
21. Gillis JC, Markham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997 Dec; 54 (6): 885-902
22. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62 (9): 1345-53; discussion 1354-6
23. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003 Jun; 17 (6): 425-32
24. The Fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993 Jan 25; 153 (2): 154-83